Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00503841 · ClinicalTrials.gov registry record · NA
Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer
A NA study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Terminated
- Registry status
- NA
- Development phase
- 44
- Enrollment target
NCT00503841 is a NA study that was terminated before completion, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 44 participants.
The verdict
NCT00503841, a NA study, was terminated before completion, sponsored by Barbara Ann Karmanos Cancer Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 44 participants
- Enrollment target
Study Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial is studying how well erlotinib works in treating women undergoing surgery for stage I, stage II, or stage III breast cancer.
Interventions
- OTHER laboratory biomarker analysis
- PROCEDURE biopsy
- OTHER immunohistochemistry staining method
- PROCEDURE conventional surgery
- DRUG erlotinib hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00503841
The ClinicalTrials.gov registry entry for NCT00503841 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00503841 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00503841 about?
NCT00503841 is a clinical study titled "Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer". RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial is studying how well erlotinib works in treating women undergoing surgery for stage I, stage II, or stage III breast cancer.
What is the current status of trial NCT00503841?
This trial is currently terminated. It is a NA study. The enrollment target is 44 participants. The study started on 2007-12. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00503841?
The interventions under investigation include: laboratory biomarker analysis (OTHER), biopsy (PROCEDURE), immunohistochemistry staining method (OTHER), conventional surgery (PROCEDURE), erlotinib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00503841?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.